Reversing cardiac hypertrophy and heart failure using a cardiac targeting peptide linked to miRNA106a

Abstract

Background: One in five adults aged 40 will develop heart failure (HF) during their lifetime. Risk factors (e.g., hypertension, diabetes mellitus, coronary artery disease, etc.) lead to structural and functional changes in cardiomyocytes, resulting in HF. At the cellular level, these changes consist of mis/over-expression of genes that regulate cardiac identity (e.g., CamK2δ, PKC, Stat3, etc.). The current paradigm for treating HF is pharmacological or device-based intervention; however, with few exceptions, the condition worsens with time. We are proposing to implement a change in HF treatment, shifting from a drug-centric system to a cardiac target-specific molecular approach that would reverse hypertrophy and adverse remodelling of affected cardiomyocytes.

Methods: A cardiomyocyte targeting peptide (CTP) was reversibly linked to miRNA106a for delivery to a mouse model of HF. Reversal of morphological, signalling, and physiological HF parameters was measured. Additionally, CTP-miRNA106a was introduced into a human cardiomyocyte cell line to identify mechanism(s) at play for reversing HF characteristics (e.g., hypertrophy).

Results: Bio-distribution studies showed that intravenously injected CTP-miRNA106 delivered its cargo specifically to the heart within 30 min, followed by clearance of CTP from the heart to the kidneys, and to a lesser extent, the liver by 35 h with persistence of miRNA106a in cardiomyocytes until day 7 (the latest tested time-point). CTP-miRNA106a reversed angiotensin2/isoproterenol-induced hypertrophy in 90% of the treated mice. We also identified two potential HF intracellular signalling pathways/mechanisms (PLCβ1/PKC/IP3 and NF-κB) targeted by CTP-miRNA106a that could benefit many pathophysiologies underlying HF, including inflammation.

Conclusions: CTP-miRNA106a, a first-of-a-kind cardiac-specific drug, downregulates genes involved in cardiac hypertrophy and inflammation through the PLCβ1 and CamKIIδ kinase pathways. CTP delivery of miRNA106a cargo is specific to cardiomyocytes both in vitro and in vivo, and once delivered, many HF parameters, including hypertrophy, are reversed.

Keywords

cardiac targeting peptide / heart failure / miRNA therapy / NF-kB

References

[1] Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020; 76(25): 2982-3021.

[2] Virani S, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020; 141(9): e139-e596.

[3] Mishra S, Kass D. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021; 18(6): 400-423.

[4] Gallicano G, et al. Reversing cardiac hypertrophy at the source using a cardiac targeting peptide linked to miRNA106a: targeting genes that cause cardiac hypertrophy. Pharmaceuticals (Basel). 2022; 15(7).

[5] Anderson M, Brown J, Bers D. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011; 51(4): 468-473.

[6] Zhang P. CaMKII: the molecular villain that aggravates cardiovascular disease. Exp Ther Med. 2017; 13(3): 815-820.

[7] Lebek S, Caravia XM, Straub LG, et al. CRISPR-Cas9 base editing of pathogenic CaMKIIdelta improves cardiac function in a humanized mouse model. J Clin Invest. 2024; 134(1): e175164.

[8] Lebek S, Chemello F, Caravia XM, et al. Ablation of CaMKIIdelta oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Science. 2023; 379(6628): 179-185.

[9] Nassal D, Gratz D, Hund T. Challenges and opportunities for therapeutic targeting of calmodulin kinase II in heart. Front Pharmacol. 2020; 11: 35.

[10] Stansfield W, Ranek M, Pendse A, et al. The pathophysiology of cardiac hypertrophy and heart failure. Cell Mol Pathobiol Cardiovasc Dis. 2014: 51-78.

[11] Tappia P, Dhalla N. Upregulation of phospholipase C gene expression due to norepinephrine-induced hypertrophic response. Cells. 2022: 11(16).

[12] Hu R, Morley MP, Brandimarto J, et al. Genetic reduction in left ventricular protein kinase C-alpha and adverse ventricular remodeling in human subjects. Circ Genom Precis Med. 2018; 11(3): e001901.

[13] Weeks K, McMullen J. Divergent effects of PKC (protein kinase C) alpha in the human and animal heart? Therapeutic implications for PKC inhibitors in cardiac patients. Circ Genom Precis Med. 2018; 11(3): e002104.

[14] Lal A, Navarro F, Maher CA, et al. miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3'UTR microRNA recognition elements. Mol Cell. 2009; 35(5): 610-625.

[15] Ventura A, Young AG, Winslow MM. et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008; 132(5): 875-886.

[16] Foshay K, Gallicano G. miR-17 family miRNAs are expressed during early mammalian development and regulate stem cell differentiation. Dev Biol. 2009; 326(2): 431-443.

[17] Foshay K, Gallicano G. Small RNAs, big potential: the role of microRNAs in stem cell function. Curr Stem Cell Res Ther. 2007; 2(4): 264-271.

[18] Divisato G, Passaro F, Russo T, Parisi S. The key role of microRNAs in self-renewal and differentiation of embryonic stem cells. Int J Mol Sci. 2020; 21(17).

[19] Larabee SM, Coia H, Jones S, Cheung E, Gallicano GI. miRNA-17 members that target Bmpr2 influence signaling mechanisms important for embryonic stem cell differentiation in vitro and gastrulation in embryos. Stem Cells Dev. 2015; 24(3): 354-371.

[20] Zhang Z, Ursin R, Mahapatra S, Gallicano GI. CRISPR/CAS9 ablation of individual miRNAs from a miRNA family reveals their individual efficacies for regulating cardiac differentiation. Mech Dev. 2018; 150: 10-20.

[21] Lorenz K, Stathopoulou K, Schmid E, Eder P, Cuello F. Heart failure-specific changes in protein kinase signalling. Pflugers Arch. 2014; 466(6): 1151-1162.

[22] Schlegel P, Reinkober J, Meinhardt E. et al. G protein-coupled receptor kinase 2 promotes cardiac hypertrophy. PLoS One. 2017; 12(7): e0182110.

[23] Cannavo A, Liccardo D, Koch W. Targeting cardiac beta-adrenergic signaling via GRK2 inhibition for heart failure therapy. Front Physiol. 2013; 4: 264.

[24] Hohl M, Wagner M, Reil J, et al. HDAC4 controls histone methylation in response to elevated cardiac load. J Clin Invest. 2013; 123(3): 1359-1370.

[25] Salazar NC, Vallejos X, Siryk A, et al. GRK2 blockade with betaARKct is essential for cardiac beta2-adrenergic receptor signaling towards increased contractility. Cell Commun Signal. 2013; 11: 64.

[26] Mattiazzi A, Kranias E. The role of CaMKII regulation of phospholamban activity in heart disease. Front Pharmacol. 2014; 5: 5.

[27] Pinilla-Vera M, Hahn V, Kass D. Leveraging signaling pathways to treat heart failure with reduced ejection fraction. Circ Res. 2019; 124(11): 1618-1632.

[28] Kreusser M, Backs J. Integrated mechanisms of CaMKII-dependent ventricular remodeling. Front Pharmacol. 2014; 5: 36.

[29] Schumacher SM, Gao E, Cohen M, Lieu M, Kurt Chuprun J, Koch WJ. A peptide of the RGS domain of GRK2 binds and inhibits Galpha(q) to suppress pathological cardiac hypertrophy and dysfunction. Sci Signal. 2016; 9(420): ra30.

[30] Zhang R, Khoo MSC, Wu Y, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005; 11(4): 409-417.

[31] Guyonnet L, Czopek A, Farrah TE, et al. Deletion of the myeloid endothelin-B receptor confers long-term protection from angiotensin II-mediated kidney, eye and vessel injury. Kidney Int. 2020; 98(5): 1193-1209.

[32] Lu H, Howatt DA, Balakrishnan A, et al. Subcutaneous angiotensin II infusion using osmotic pumps induces aortic aneurysms in mice. J Vis Exp. 2015: (103): 53191.

[33] Zhou Q, Pan L, Xue R, et al. The anti-microbial peptide LL-37/CRAMP levels are associated with acute heart failure and can attenuate cardiac dysfunction in multiple preclinical models of heart failure. Theranostics. 2020; 10(14): 6167-6181.

[34] Li J, Sha Z, Zhu X, et al. Targeting miR-30d reverses pathological cardiac hypertrophy. EBioMedicine. 2022; 81: 104108.

[35] Dewenter M, Pan J, Knödler L, et al. Chronic isoprenaline/phenylephrine vs. exclusive isoprenaline stimulation in mice: critical contribution of alpha(1)-adrenoceptors to early cardiac stress responses. Basic Res Cardiol. 2022; 117(1): 15.

[36] Mahapatra S, Sharma MVR, Brownson B, Gallicano VE, Gallicano GI. Cardiac inducing colonies halt fibroblast activation and induce cardiac/endothelial cells to move and expand via paracrine signaling. Mol Biol Cell. 2022; 33(11): ar96.

[37] Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. Int J Mol Sci. 2019; 20(8).

[38] Mehta N, deGoma E, Shapiro M. IL-6 and cardiovascular risk: a narrative review. Curr Atheroscler Rep. 2024; 27(1): 12.

[39] Hussain L, Rana S, Abbas G. et al. Pharmacological potential of Hippophae rhamnoides L. nano-emulsion for management of polycystic ovarian syndrome in animals’ model: in vitro and in vivo studies. ACS Omega. 2023; 8(36): 32977-32989.

[40] Taylor R, Zahid M. Cell penetrating peptides, novel vectors for gene therapy. Pharmaceutics. 2020; 12(3).

[41] De Mello W. Renin-angiotensin system and cell communication in the failing heart. Hypertension. 1996; 27(6): 1267-1272.

[42] Mello WD, Altieri P. The role of the renin-angiotensin system in the control of cell communication in the heart: effects of enalapril and angiotensin II. J Cardiovasc Pharmacol. 1992; 20(4): 643-651.

[43] Hayden M, Ghosh S. Regulation of NF-kappaB by TNF family cytokines. Semin Immunol. 2014; 26(3): 253-266.

[44] Ek-Vitorin JF, King TJ, Heyman NS, Lampe PD, Burt JM. Selectivity of connexin 43 channels is regulated through protein kinase C-dependent phosphorylation. Circ Res. 2006; 98(12): 1498-1505.

[45] Zhong C, Zhao H, Xie X, et al. Protein kinase C-mediated hyperphosphorylation and lateralization of connexin 43 are involved in autoimmune myocarditis-induced prolongation of QRS complex. Front Physiol. 2022; 13: 815301.

[46] Viczenczova C, Kura B, Chaudagar KK, et al. Myocardial connexin-43 is upregulated in response to acute cardiac injury in rats. Can J Physiol Pharmacol. 2017; 95(8): 911-919.

[47] Pun R, Kim M, North B. Role of Connexin 43 phosphorylation on Serine-368 by PKC in cardiac function and disease. Front Cardiovasc Med. 2022; 9: 1080131.

[48] Rusciano M, et al. CaMKII activity in the inflammatory response of cardiac diseases. Int J Mol Sci. 2019; 20(18).

[49] Ling H, Gray CB, Zambon AC, et al. Ca2+/Calmodulin-dependent protein kinase II delta mediates myocardial ischemia/reperfusion injury through nuclear factor-kappaB. Circ Res. 2013; 112(6): 935-944.

[50] Braz JC, Gregory K, Pathak A, et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med. 2004; 10(3): 248-254.

[51] Boengler K, Hilfikerkleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther. 2008; 120(2): 172-185.

[52] Shi J, Wei L. Regulation of JAK/STAT signalling by SOCS in the myocardium. Cardiovasc Res. 2012; 96(3): 345-347.

[53] Liu C, Tang W. Epigenetics in cardiac hypertrophy and heart failure. JACC Basic Transl Sci. 2019; 4(8): 976-993.

[54] Dahl EF, Wu SC, Healy CL, Harsch BA, Shearer GC, O'Connell TD. Subcellular compartmentalization of proximal Galpha(q)-receptor signaling produces unique hypertrophic phenotypes in adult cardiac myocytes. J Biol Chem. 2018; 293(23): 8734-8749.

[55] He X, Du T, Long T, Liao X, Dong Y, Huang Z. Signaling cascades in the failing heart and emerging therapeutic strategies. Signal Transduct Target Ther. 2022; 7(1): 134.

[56] Harhous Z, Booz GW, Ovize M, Bidaux G, Kurdi M. An update on the multifaceted roles of STAT3 in the heart. Front Cardiovasc Med. 2019; 6: 150.

[57] Hiscott J, Marois J, Garoufalis J. et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol Cell Biol. 1993; 13(10): 6231-6240.

[58] Fiordelisi A, Iaccarino G, Morisco C, Coscioni E, Sorriento D. NFkappaB is a key player in the crosstalk between inflammation and cardiovascular diseases. Int J Mol Sci. 2019; 20(7).

[59] Willeford A, Suetomi T, Nickle A, Hoffman HM, Miyamoto S, Heller Brown J. CaMKIIdelta-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis. JCI Insight. 2018; 3(12).

[60] Guan X, Wang L, Liu Z, et al. miR-106a promotes cardiac hypertrophy by targeting mitofusin 2. J Mol Cell Cardiol. 2016; 99: 207-217.

[61] Sethi K, Cram E, Zaidel-Bar R. Stretch-induced actomyosin contraction in epithelial tubes: mechanotransduction pathways for tubular homeostasis. Semin Cell Dev Biol. 2017; 71: 146-152.

[62] Lu M, et al. https://biorender.com/f0pdv1J

[63] Wang Y, Brichacek B, Dubrovsky L, et al. Increased atherosclerosis in HIV-infected humanized mice is caused by a single viral protein, Nef. J Infect Dis. 2025

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.